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Targeted Temperature control for post cardiac arrest patients has a long history dating back to 
the ancient Greeks. In the last twenty years there has been a push to define and implement a 
protocol for targeted temperature control for post cardiac arrest patients, specifically those with 
ventricular fibrillation arrests, to improve neurological outcomes and post-arrest quality of life. 
In this review, literature from the last twenty years and beyond was examined to attempt to 
determine whether populations treated with therapeutic hypothermia experienced improved 
neurological results.  
Methods 
Literature searches were preformed using the PubMed database as well as Google Scholar.  
Conclusion 
Based on the current research, it was determined that the field of therapeutic hypothermia has 
significant shortcomings in research based on overall applicability and potential benefit. In its 
current form, therapeutic hypothermia is weakly recommended by governing health authorities 
and does not appear to offer any significant benefit on neurological outcomes for patients 
suffering from out of hospital ventricular fibrillation cardiac arrest.1 Implementation of therapy 
was found to be associated with significant risks to the patient in terms of complications, hospital 
stay, mortality, and cost.2-4 All this considered, it seems that the future of TTM hangs in the 
balance. Further randomized research trials are needed within the field to conclusively determine 
whether or not therapeutic temperature management has a role in revised cardiac arrest protocols 
moving forward.     





 The role of temperature modulation, specifically the of cooling the body, in limiting 
injury is an idea that is as old as the Greeks.5 As kids we can all recall a time that we banged up 
our knee or hit our head and our guardians placed a bag of ice on our injury to help quell the 
. I           l to use 
cooling to help prevent damage from internal injuries more serious than a simple bruise or bump. 
Induced hypothermia and its role in the modulation of cytokine and norepinephrine release is a 
long-studied topic that has its roots in animal models. It has long been demonstrated that 
temperature regulation of the body plays a significant role in managing and controlling 
neurotransmitter release, uptake, and impact across the CNS.6  
Studies involving hypothermia and brain activity related to oxygen consumption date 
back to the early 1950s where a linear decrease in oxygen demands by the brain was 
demonstrated         35C  26C .7 The first 
studies conducted on humans were performed in 1958 and demonstrated that for the 19 tested 
individuals in asystole or fibrillation, cooling of the body improved histopathological findings in 
at least 7 of the patients.8 Limited systemic support and marginal evidence for the consistent 
practice of therapeutic hypothermia    2002  two studies published in the 
NEJM demonstrated a significant improvement in neurological outcomes. One study found that 
cooling of patients to at least 33C within two hours of ROSC improved neurological outcomes 
for 49% of participants.9 The second, found that neurological outcomes for individuals cooled to 
32-34C had significantly increased neurological outcomes as measured by the Pittsburgh 
cerebral-performance categorization for patients who had ventricular fibrillation arrests (See 
Appendix 1 for data).10  The demonstrated benefit in neurologic outcomes was not only found in 
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the days immediately following arrest, but tracked for up to 6 months following the arrest and 
recovery.10  
Following these two landmark studies, continued research in the field has been focused 
on timing, levels of neuroprotection, rates of recovery, and appropriate populations for use of 
therapeutic hypothermia.1,4,11-15  This paper will explore the underlying pathophysiology of 
therapeutic hypothermia as well as the current field of hypothermia with focus on the 
demonstrated benefit to neurological outcomes of cooling during post-arrest resuscitation care. 
Part of the focus will be on why this field was particularly hot in the early to mid 2000s and has 
since taken a backseat to newer protocols. In terms of patient population for this research the 
plan is to focus primarily on adults aged (18+) who suffered out of hospital arrests (OHCA) due 
to ventricular fibrillation. These demographic criteria were derived in part because ventricular 
fibrillation was the rhythm of focus in early studies of therapeutic hypothermia and this 
population subset was where a majority of the work on therapeutic hypothermia has been 
centered thus far.10  
BACKGROUND  
Pathophysiology of cellular signaling: 
The theory that modulation of cellular signaling plays a large role in post arrest care 
occupies the majority stake in our understanding of the potential benefit of therapeutic 
hypothermia. Early animal studies demonstrated a clear link between NE and 5-HT levels, and 
temperature of the body tissues, where lower levels of NE and 5-HT were associated with colder 
temperatures of tissues.6 The apparent link between cooler temperatures and patient outcomes 
was first demonstrated in a human model in 1958 when Benson et al., published that 
hypothermic temperatures in post- post arrest patients showed a better neurological outcome.8 
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T      understanding of the exact mechanisms of benefit until the mid 1980s 
when it became more clear as to what implications the differing levels of neurotransmitters may 
have on neurological functioning and control. That being said, it was universally accepted at the 
time that in post-resuscitation patients, control of CNS damage was the key to better outcomes 
and survival. Post-         1980     
CNS  likely manifested in upregulation of NE and 5-HT      
           of which are contributing 
factors to poor outcome.16  The thought is that when the body encounters an ischemic stress, like 
that which would occur during a cardiac arrest or rhythm abnormality, the stress response is 
mediated by inflammatory cytokines leading to an increase in NE and 5-HT.17 A study from 
2012 found that induction of heart cells chilled to a rather substantial 17C with the inflammatory 
trigger lipopolysaccharide resulted in significantly less inflammation activation and damage 17. 
They went on to point out that dramatic increases in LPS dosing to the cells were associated with 
stark increases in NE and 5-HT levels.17  Overall, this would result in an overall increased 
oxygen and energy demand from the tissue.17 This experiment showed in a microcosm, that 
tissue that is struggling to meet energy requirements for metabolism will kick start a vicious 
cycle of damage.  
The increase in NE takes place via two primary mechanisms. One is calcium dependent 
electrical exocytosis mediated, the second is calcium independent carrier mediated.17  The latter 
of these two mechanisms is the more common route of response in the case of ischemic damage. 
Where hypothermia comes into play here is slowing down the more common route of 
norepinephrine release within the tissues, with the end result being a decreased level of energy 
and oxygen required by the tissues.5,17  
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The second half of therapeutic temperature control is centered on preventing damage on 
tissue rewarming. Bringing the body back to normothermic temperatures is associated with an 
           .18 As 
tissue is rewarmed, the body slowly starts to implement its own thermoregulatory measures to 
increase body temperature, which can result in the development of increased oxygen 
consumption, decreased cellular glucose concentrations, and an overall overcorrect in body 
temperature and activity.18 The net result of this overcompensation by the body is further damage 
that plays into worse outcomes both in terms of neuroprotection and survival.18  The cycle of  NE 
and 5-HT damage is perpetuated again on rewarming, which stresses the importance for control 
when returning the body to normothermic levels post- TTM treatment. Protocols to prevent 
bodily overcompensation in terms of thermoregulatory control will be discussed in further detail 
  M   T  T  C   .  
Defining the Patient Population 
The primary goal of this section is to explain the focused patient population for 
therapeutic hypothermia. More discussion on the specific influence of the studies in therapeutic 
hypothermia will be included below. The population for therapeutic hypothermia is primarily 
defined based on the two hallmark studies within the field which will be discussed below. The 
majority of other studies and analysis of TTM cite these initial two studies in their methods to 
define patient population so it would be redundant to spend much time on the study populations 
of other publications.  
In 2002 Bernard et al., and the HACA group published the first two substantial studies in 
therapeutic hypothermia.9,10 The two studies shared the enrollment requirement that a patient had 
to be in a documented ventricular fibrillation rhythm, after which ROSC had to be achieved prior 
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to randomization into either the hypothermic or normothermic groups.9,10 All patients enrolled 
were between 18 and 75 for the HACA group study. Bernard et al., was even more specific in 
their patient population by only enrolling male patients 18 years of age or older, and enrolling 
only females who were over 50 to eliminate secondary complications from potential 
pregnancy.9,10 Patients were then randomly placed into either the treatment group (TTM) or the 
normothermic group (regular ICU care for post-cardiac arrest) based on their demographics.9,10 
Exclusion criteria from both studies included evidence of hypotension greater than 60 
mm Hg for longer than 30 minutes, other possible causes for coma including drug overdose, 
cerebral -vascular accident, signs of head trauma, and evidence of hypoxemia for a period of 
longer than 15 minutes with SpO2 saturation less than 85%.9,10 Interestingly, the HACA group 
also excluded patients regardless of demographics if there was not an available ICU bed within 
the participating facilites.10 Randomization for treatment selection was done by day of the month 
at time of presentation for the Bernard et al., study and via a 10 block computer randomization 
based on facility for the HACA study.9,10 As mentioned previously, subsequent studies to follow 
the aforementioned work typically included the same inclusion and exclusion criteria with 
minimal variance.  
Demonstrated Benefit of Hypothermia 
One of the earliest reviewed studies in 1959 involved taking a close look at the underlying brain 
pathology and changes of four cardiac arrest patients. 19 The histology findings of post arrest 
brain tissue found that increased swelling, brain volume, and subsequent herniation following 
anoxia during arrest was largely contributory to a worse outcome and death in the four patients 
within the study. 8 As previously mentioned this pathology research, coupled with early studies 
of accidental hypothermia in mouse and dog models provided the backbone for the early push 
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towards TTM protocols in humans.6-8 The initial human trials limited participants to those in 
asystole or confirmed fibrillation via open chest visualization.8 Outcomes were tracked using a 
             
  ,  ,  .8 Twenty-seven patients in total were 
followed throughout the study, fifteen of which were not cooled, and twelve who were.8 Of the 
twelve who received cooling, six survived with some neurological damage, whereas only one of 
the patients without cooling survived with neurological damage.8 This study really put some 
wind in the sails of TTM research and proved that for patients suffering some degree of 
neurological damage post-arrest, hypothermia had a clinically significant ability to improve 
survival.8   
Research on human subjects with regard to TTM was relatively quiet again from the early 
60s until 2002 when two hallmark studies published in NEJM further proved efficacy of TTM 
protocols in post arrest patients.9,10 The first found that for 75 of the 136 patients enrolled in 
TTM post-successful ventricular fibrillation arrest resuscitation, there was improved neurological 
outcomes when calculated using the Pittsburgh scale of cerebral performance.10 The second 
study found that 21 out of 43 patients who were induced to hypothermia following successful 
ventricular fibrillation resuscitation had a favorable outcome based on disposition.9 Patients were 
considered to have a favorable outcome in this study if they were discharged home or to short 
term rehab care post recovery, as opposed to being sent to long term skilled nursing or suffering 
in-hospital death.9 T    ,   D . H    
TTM from 2010, and Silverman et al from 2016 are the table legs that support TTM guidelines 
as they currently stand.20,21 Holzer published what were, at the time, the first inklings of 
standardized care for patients to undergo TTM. The patient criteria, cooling levels, methods, and 
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timing were all laid out in one place, providing a quick guideline for clinicians looking to 
establish TTM as part of their care regimen. These recommendations later led to the 
establishment of TTM as part of ILCORs cardiac arrest guidelines.20 The guidelines were 
updated a final time in 2015, and are currently in line with how post-arrest therapeutic 
management is handled today.1 Silverman et al piggy backed off of Holzer and published a more 
refined version of the guidelines further exploring current research on TTM in 2016, again 
focusing on timing, methods, and reported benefit.21 A 2013 study conducted by Nielsen et al., 
which involved recruitment of patients from 36 ICU facilities across Australia and Europe 
expanded on previous success within the field by attempting to determine optimal cooling 
temperature.22 Enrollment criteria was determined via GCS scoring on arrival to the hospital.22 
Patients were randomized into one of two groups: Cooling to 33C or Cooling to 36C.22 In sum a 
total of 950 patients were enrolled between 2010 and 2013, 476 assigned to the 33C group and 
474 to the 36C group.22  This study varies from the previous benchmark studies from 2002 in 
terms of control grouping, and though they were not able to determine a significantly different 
outcome between 33C and 36C, Nielsen et al., did point to the fact that compared to no cooling 
at all, 33C or 36C may exhibit benefit.22 All the previous research led up to a relatively recent 
Cochrane review published by Arrich et al.,  which included data from RCTs conducted by 
Bernard et. al, the NEJM, and Nielsen et al, and calculated the perceived benefit across these 
studies in terms of neurological outcomes.9,10,12,22  Inclusion criteria for the review included 
           
 ,  ,  ,    ,   . 12 
Arrich et al., categorized primary neurological outcomes into five different categories consisting 
of the following:12  
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x Good cerebral performance: conscious, alert, sufficient function for ADLs, no significant 
compromise  
x Moderate cerebral disability: Conscious, alert, may have hemiplegia, ataxia, seizures, 
dysarthria, or permanent memory loss. 
x Severe: Conscious with at least limited cognition. Dependent on others for ADLs with a 
wide range of abnormalities.   
x  Coma or Vegetative state: Not conscious or unaware of surroundings, no verbal or 
psychological interaction with the environment.   
x Certified Brain Death. 
The above listed neurological categories were then used in their analysis of the RCTs to 
determine the impact of TTM on neurological outcomes.12 With results pooled and  data 
restricted for heterogeneity between control groups within the aforementioned studies, Arrich 
et al., found that cooling to at least 33C was superior to no cooling or temperature 
management to 36C.12 All of this led to their conclusion that there is in fact moderate 
evidence that suggests that conventional cooling methods do in fact improve neurological 
outcome post cardiac arrest, specifically when compared to no temperature management.12 
Given the previous discussion, the role of therapeutic hypothermia is still rife with 
conflicting options. Mitrani et al., is quick to make the point that despite proven success with 
TTM in post VT/VF patients as well as animal models, TTH     
           illation and better risk 
stratification on cardiac patients are the key to better outcomes.23  
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Counter Argument: Targeted Temperature Management Proves Ineffective  
For all the research that points to the fact that there may be some demonstrated benefit in 
terms of neuroprotection and survival for TTM patients, there is just as much, or potentially even 
more evidence that points to the fact that cooling is hardly effective. The core issue with a large 
portion of TTM research seems to be that there is little to no consensus on what it actually means 
for a patient to undergo TTM. Taccone et al.,         
physicians consider mechanism, route, dose,      TTM  
      (S   2  ).24 Not only is it difficult to 
evaluate evidence based on the different protocols used, but timing, patient populations, and 
inclusion criteria seem to be constantly variable between studies. All of this combines to make it 
extremely difficult to draw any significant conclusions on efficacy. When rating evidence for 
ALS   TTM, ILCOR      -qua     
following categories related to OHCA with and without shockable rhythm: survival with 
favorable neurological outcomes, survival, and survival to hospital discharge.1 Many of the 
studies used to formulate the ILCOR recommendations were downgraded in their applicability 
due to significant heterogeneity in not only inclusion criteria, but also methods, neurological 
,        the patient.1  The ILCOR committee did 
            
,         RCT  939   
cooling to 33C vs 36C.1 Similar skepticism was echoed by Bhattacharjee et al., when they 
analyzed the findings of four RCTs on TTM, including the aforementioned landmark studies 
performed by Bernard et al., and HACA 2002.3  They found no associated benefit to TTM on 
patient neurological outcomes, and actually found a higher incidence of pneumonia in patients 
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who had undergone cooling protocols, further complicating recovery.3 An even more recent 
meta-analysis done by Kalra et al., compared both hypothermia and normothermia as well as pre-
hospital and in-hospital start of cooling protocols and found no benefit in neurologic outcomes or 
mortality.4 This analysis looked at 11 different RCTs in which 4782 participants were involved 
in total.4 The implications of little to no benefit with TTM go beyond that of simply just health 
outcomes as well. Kalra et. al., also called to attention the fact that many of the current protocols 
in place for inducing TTM while a patient is in the post-resuscitation phase come with a hefty 
price tag (sometimes upwards of 160k).4  
Timing of Targeted Temperature Management 
Timing of Targeted Temperature Management has also proven to be an inconsistent and 
contentious topic in the literature. Early studies showed benefit (in dogs) if cooling was initiated 
for 24 to 48 hours, but more recent research and improvements in cooling technology have 
created a rift in temperature management protocols.8 Even within the landmark studies 
performed by Bernard et al., and HACA in 2002 temperature goals and duration differed, 
introducing rather significant heterogeneity into the field.9,10 Bernard et al., cooled patients to a 
goal temperature of 33C, whereat this temperature was maintained for 12 hours before the body 
was actively rewarmed for at least six hours beginning at the 18 hour mark.9 The HACA group 
on the other hand had the goal temperature of between 32C and 34C, which was maintained for 
at least 24 hours prior to undergoing at least eight hours of passive rewarming.10 More recent 
research has been targeted at the potential benefits of starting cooling for OHCA prior to hospital 
arrival.  A 2019 Cochrane review conducted by Arrich et al., on neuroprotection and the impacts 
of timing attempted to look for a more conclusive timing framework for best patient outcomes.11 
Looking at 2369 participants over seven RCTs conducted from 2007 to 2014 found that for out 
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of hospital cardiac arrests due to ventricular fibrillation or asystole, there was no evidence to 
support earlier or later cooling for neurological outcomes.11 Though multiple of the RCTs looked 
at in this review pointed to some benefit of earlier cooling, likely linked to decreased in-hospital 
cooling times to reach target temperature, this Cochrane review found the opposite was true.25-29 
In fact, they found that there appeared to be no consistency across the seven RCTs on when, if, 
and how treatment protocols for therapeutic hypothermia were initiated.11 Of note, the seven 
RCTs are of significance as they proved feasibility and safety of implementing cooling outside of 
the hospital.25-29 Arrich et al., in their review also encountered issues drawing any conclusion 
from the seven RCTs mentioned previously, as implementation and enrollment into the protocol 
for therapeutic hypothermia was largely left up to the attending physician, introducing significant 
potential for bias.11 Duration of cooling also remains a rather contentious topic. As mentioned 
above, there is significant variance in the accepted duration of cooling for greatest efficacy. 
Bernard et al., kept temperatures at hypothermic levels for 12 hours, where the HACA trial found 
efficacy with 24 hours of cooling.9,10 Nielsen et al., similar to the HACA trial maintained 
temperature for 24 hours before beginning the rewarming phase.22 In general, it seems there is a 
belief that cooling must hold a duration of at least 24 hours to be acceptable.24 The most recent 
guidelines on cardiac arrest care from ILCOR echo this sentiment, drawing on both Nielsen et 
al., and the NEJM study to formulate their recommendation that for any patient undergoing TTM 
  ,      24 .10,13,22 Of note, this guideline was given 
      ILCOR ,       re 
     in support of a 24hr duration.1 Similarly to many of the other 
shortcomings of therapeutic hypothermia, induction time, duration, and speed at which TTM is 
induced suffers from a general lack of evidence from long term RCTs.   
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Methods of Targeted Temperature Management 
 Typical protocols for TTM involve both management of temperature and the 
sedation/control of the human shivering response. There is a fair degree of variability in 
methods, but its universally accepted that sedatives play a key role in all therapeutic hypothermia 
protocols.24 According to a 2020 study on TTM post cardiac arrest, there are does not appear to 
be any benefit to one specific sedative formulation.24 Some associated risk was seen in the 
hemodynamics with the use of propofol for sedation, but this does not appear to be linked with 
any specific instances of worse prognosis.24 Along with sedation, its common to control 
shivering response during initiation and the rewarming phase when close to or below 
normothermic levels.24 This is commonly done with another low dose sedative like a  
benzodiazepine, in conjunction with alpha-2-agonnists and intravenous magnesium dosing.24 
Attempts to prevent shivering are taken relatively heavy handedly, as shivering is thought to be 
               
           
neuroprotective benefits of targeted temperature management.30 Pharmacologic treatments and 
         A  3      
 .30 Outside of pharmacologic measure, shivering can be controlled via external 
measures such as cutaneous warming at the extremities while core temperatures at hypothermic 
goal are maintained.30 This is largely possible as 20% of shivering response is triggered by 
external skin temperatures, and if this variable can be controlled, rates of shivering are 
decreased.30 The breadth of methods to achieve the active, high quality targeted temperature 
management of the patient are plentiful and wide reaching from invasive, to external, to full on 
dialysis.24  M         .31  C   
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include cold IV fluids, automated peritoneal lavage, hemodialysis with cooling, extra-corporeal 
membrane oxygenation, and esophageal/ trans-nasal evaporative cooling.31 S   
include skin exposure, chilled beds, ice packs in axillary regions, cooling pads, air and water 
filled blankets, and water-circulation vests and beds.31 Additionally, within the two main 
    ,          
  .31 I       
peritoneal lavage, dialysis, and extra-corporeal oxygenation.24,31 T   
  TFD         ,    
     -stop monitoring and automatic adjustments of 
temperature.31 I               
            
.31 That being said, there was significant heterogeneity between the key studies 
mentioned previously in terms of cooling methods.  
METHODS 
 Literature searches were conducted primarily using the PubMed literature database. 
K     , ,  , 
, , , ,  . I limited my searches to 
include only articles in which I had access to or could obtain access to the full text from the 
source of publication. Multiple of the articles had to be requested via interlibrary loan via 
A  U  L  L . Overall initial searches netted 431 articles. I narrowed 
down the initial search results further via abstract review for those I felt fit well into my research 
topic. A large portion of the initial article research was conducted using two sources from the 
Cochrane Library of Reviews and then examining the cited randomized control trials and 
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reviews for inclusion in this paper 11,12. I attempted to limit my research to the past fifteen years 
but expanded my criteria to provide some historical context for the ideas and foundations of 
therapeutic hypothermia in the field of cardiac arrest. Upon gathering my articles, each was 
reviewed for relevant information and data. Screenshots of tables I found particularly useful were 
included in the Appendix attached at the end of this document. All articles used in this paper 
were cited in-text and in the references section in JAMA format via EndNote X9 citation 
software.   
DISCUSSION 
In this section I hope to address the following issues: is there legitimacy to TTM 
protocols as they stand today, does TTM have a future with continued research, and why is 
implementation of TTM lacking across the board? As I see it currently, there are realistically two 
different camps when it comes to TTM. There are those who point to the fact that much of the 
research on TTM is inherently flawed and marginally statistically significant at best, and there 
those who argue that even a minimal neurological outcome improvement is better than nothing 
considering the circumstances the patient faces after having a cardiac arrest has on the body.  
Evaluation of Evidence on Cooling 
Looking strictly at the data that support the implementation of TTM, the common thread 
among these studies is that while it may not be possible to perfect the assessment of treatment on 
survival, there are some positive findings in terms of neurological status. Interestingly, the four 
most prominent studies regarding TTM all used the Cerebral Performance Category score when 
grading the outcomes of the enrolled patients.9,10,20,22 Lower CPC scores in general are 
considered a fairly strong predictor for out of hospital survival post cardiac arrest, though the 
CPC scoring system suffers from the same pitfalls of bias that any clinician decision based 
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scoring system suffers from.32 A sample CPC scoring system is included in Appendix 4 for 
reference. Both the study done by the HACA group and Bernard et al., used a randomization and 
blinding process for evaluation of outcomes, which helps strength their evidence of positive 
neurological outcomes.9,10 Interestingly, Nielsen and Holzer make no mention of attempts to 
blind evaluators to the patients treatment status.20,22 It is important to keep in mind that while the 
physicians and neurologists who performed the grading on patients neurological may try to 
maintain as much objectivity as possible, there is still the risk that personal bias may be a factor 
when grading is done using a largely subjective scale like the CPC. Scoring bias aside, it 
becomes increasingly difficult to make a true judgment call on TTM when you look strictly at 
the numbers. Bernard et al., found that 21 of 43 patients who underwent TTM were graded 
higher CPC scores.9 This was considered statistically significant (p-value 0.046)   
by the researchers.9 Similarly, the HACA group found that of the individuals who underwent 
TTM, 75   136 (55%)   CPC ,     .10 
Looking then to Nielsen, a study that had significantly higher enrollment, they found 235 of 473 
(50%) in the 33C treatment group saw increased CPC scores.22 Where this becomes increasingly 
interesting is they determined that 50% of patients seeing neurological improvement is not 
enough to declare a substantial finding in terms of the efficacy of cooling.22 These three studies 
bring to light the fact that not only is there a risk for evaluation bias with patients, there is a risk 
of individual perception and bias when evaluating the statistics as well. It becomes increasingly 
tough to formulate a treatment decision when a handful of studies say that 50% of the treatment 
subpopulation is a significant number, whereas other studies say that 50% is not in fact enough 
of a benefit to pursue treatment on a broader scale.9,10,22  
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Using the three aforementioned studies, as well as two additional smaller RCTs, Arrich et 
al., were able to come to the conclusion that there is minimal-moderate evidence that cooling 
post-arrest improves outcomes compared to cooling.12 Even with a substantial amount of work 
done on analysis and risk- bias grading by Arrich et al., it still seems difficult to make a 
conclusive decision on cooling due to the fact that there was significant heterogeneity in control 
groups between the studies analyzed.12 Though there appears that there is some demonstrated 
benefit to cooling below normothermic body temperatures, the authors acknowledge the fact that 
            .12 A 
second meta-analysis done by Bhattacharjee et al., used most of the same studies looked at in the 
Arrich et al., Cochrane review, but instead of looking at the data from the viewpoint of patient 
meta-analysis by rhythm and cause of arrest, as Arrich et al., did, they examined the data 
holistically, not taking into account what the origin of cardiac arrest was.3,12 Bhattacharjee et al., 
figured that if there is supposed benefit seen in cardiac arrest of a specific rhythm, there should 
          . 3  What they found 
instead contradicted the proposed benefits seen by Arrich et al., in that there was no benefit to 
cooling the body in terms of neuroprotection, and there was an increased in rate of potential 
adverse effects such as pneumonia.3 Two studies using similar patient data sets, but looking at 
the onset of arrest slightly differently then come to two very different conclusions. Both of these 
meta-analyses show once again one of the most prominent, and rather ugly problems in the field 
of Therapeutic Hypothermia: the outstanding heterogeneity between individual studies when it 
comes to implementation, protocols, and analysis of the outcomes. As evidenced above, there 
seems to be a fine line between perceived benefit of therapeutic hypothermia. The lack of 
consistency in interpretation of patient numbers despite the use of a relatively standardized 
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system calls to question whether the potentials for additional cost and adverse effects for the 
patient are truly worth the seemingly measly upside.  
Adverse Effects: Downsides of Therapeutic Hypothermia 
One of the themes found in research that supports Therapeutic Hypothermia is the 
relative lack of acknowledgement of the potential side effects of the induction of treatment. On 
one hand, this makes some sense as patients that meet criteria for TTM are already not doing 
very well, but on the other hand if the adverse effects are worsening the chances of recovery, 
then any found benefit of TTM seems like a moot point. The goal of TTM remains preservation 
of neurological capability post-arrest, but may subject the body to increased platelet dysfunction, 
sepsis, pneumonia, hypokalemia, and potential for further arrythmias.3 Further, an international 
task force that met in 2011 to discuss TTM found that hypothermia may also have significant 
impacts on serum amylase, insulin levels, and renal filtration.33 While these changes in 
homeostasis may be insignificant individually in the post-arrest patient, the combination of all of 
them may further complicate resuscitation and recovery efforts. A look at two RCTs involving 
1204 patients who received TTM found that 48% of patients developed pneumonia post-
hypothermia treatment.3 This resulted in a decreased CPC score at the one month mark, and 
while it increased cost of care and duration of care for the patients, has not yet been found to 
have any lasting impact on mortality.2 Another knock against the generalized use of hypothermia 
protocols comes from 2017 study from Chan et al., that found that for in-hospital cardiac arrests, 
induction of hypothermia was associated with a lower rate of survival to discharge, and less 
favorable neurological outcomes.14 A great deal of the risk of therapeutic hypothermia also 
comes from the rewarming period.  
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Obviously, we cannot keep our patients at hypothermic temperatures indefinitely, and the 
rewarming period comes with an increased risk of developing electrolyte abnormalities leading 
to the potential for developing a second arrythmia during the recovery period.4 The risk of 
rewarming then could be avoided entirely if it was determined that cooling the body in the first 
place gives no foreseeable benefit.4 Kalra et al., make probably one of the most compelling 
arguments for why therapeutic hypothermia might not actually be all that beneficial.4 They point 
to the fact that maybe the benefits we see with TTM are not actually from cooling the body, but 
        -cardiac arrest care where they were 
 .4 This theory seems particularly compelling when we consider the benefits 
other critical care arenas have experienced when they have transitioned to protocol driven 
treatment algorithms (i.e. sepsis, stroke, DKA). A standardized set of rules for post-arrest 
treatment might be all we really require to improve neurologic and survival outcomes for post-
arrest patients. Impacts on mortality aside,  important to also consider the duration of hospital 
stay and cost of care when looking at TTM with a critical eye. As always, it is essential that the 
patient or  family is properly briefed on potential outcomes before induction of any 
treatment.   
Impacts of Cost:   
Though it might sound rather grotesque to be discussing the potential incurred costs when 
talking about a lifesaving intervention, I think it is important to remember that cost is a burden 
that will have to be carried by someone, whether that is the patient or family. As is likely the 
case with many critical care interventions, or any hospital intervention for that matter, 
therapeutic hypothermia comes with a rather large associated cost. Not only that, but a study 
looking at healthcare outcomes in Korea found that individuals with lower income status and 
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lower paying state insurance were less likely to undergo TTM, and had worse outcomes when 
compared to those who held employer granted insurance through the NHI.34 Higher paying 
insurance in the post-cardiac arrest setting was associated with a 4.4% increase in 
implementation of TTM, a 6.8% increase in positive neurological outcomes, and a 6% increase 
in survival to time of discharge.34. While this study was done in Korea where there are only two 
categories of health insurance,  easy to see how a similar idea could be expanded to the 
United States where health insurance and healthcare access disparities are even more 
prominent.34 As much as nobody likes to acknowledge it, money talks and health disparities and 
access of care continue to be massive hurdles in the healthcare field This rings especially true 
when we consider the potential costs of TTM treatment.  
Depending on the methods of cooling, cost can vary from anywhere to $100,000 up to 
$165,000.35 Conventional blanket cooling was found to be around $108,000 with the more 
invasive methods like dialysis or lavage costing upwards of $140,000.35 These numbers include 
the equipment and procedural costs as well as the associated staffing, staff training, boarding, 
and administration costs associated with a typical multi-day post resuscitation hospital stay (see 
Appendix 5 for some of the associated costs).35 Several studies have taken the pricing for 
therapeutic hypothermia and put it up against neurological outcome and mortality data. Though 
both of these studies were relatively limited in their assessment of neurological outcomes due to 
          (CPC   1  
2)   (CPC    3  4)      up with a cost per quality of life 
number (or quality adjusted life years).35,36 One study found that based on conventional treatment 
with cooling blankets the patient with therapeutic hypothermia gained 0.66 years of potential 
benefit with the incurred cost of $31,254, which expanded for a full year of life comes to 
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$47,168.36 The second focused more on the cost of peritoneal lavage where they concluded that 
based on cost per improvement of neurological outcome, peritoneal lavage was the best option 
for QALY (quality adjusted life years) cost.35 The total QALY for peritoneal lavage for a year of 
improved outcome was $58,329.35 Additionally, both numbers for QALY are likely to be a little 
conservative considering they considered a normal ICU stay post-resuscitation with or without 
hypothermia protocol to be four days maximum which seems awfully ambitious.35,36 Further, 
both studies assumed no further complications for the patient, which would lead to additional 
cost and increased hospital stay.35,36  
What this all boils down to then is this: Therapeutic hypothermia is effective for roughly 
50% of the population who has suffered a cardiac arrest, and for those 50% the cost of an 
additional year of life with a CPC 1 or 2 neurological outcome will likely be north of $50,000. 
Keeping in mind that a CPC score of 2 includes some moderate disabilities and difficulties with 
ADLs, there begins to be a rather thin line that must be walked by providers and  
families alike. Can we put a number on an additional year of life? Are we justified doing so if the 
treatment that we are advocating for is no more effective than a flip of a coin? It is essential as 
future providers that we consider not only the efficacy of the treatment modalities we suggest to 
our patients and their families, but we must also keep in mind the associated financial burdens. 
There is some hope for reduced financial as TTM protocols continued to become more refined 
and cost effective. A study from 2011 found that a combination of gastric cold water lavage and 
surface cooling via evaporation and cooling blankets was just as safe, effective, and far more 
cost efficient than using strictly more expensive invasive measures like dialysis or ECMO.37  
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The Future of the Field 
In order to properly discuss the future of the field of TTM,  important to consider one 
last time the significant amounts of heterogeneity that have been noted in this paper many times 
so far. In order for there to be any real future for the use and improvement of TTM there needs to 
be some form of standardization in terms of implementation and the protocols for care. As noted 
by Taccone et al., previously, in order to move forward there has to be a consensus on what 
  TTM  .38 When writing the most recent ILCOR recommendations, there was a 
   , ,      TTM       
         TTM .1 The same can be said for specific 
temperature targets, initial rhythm presentation, or conclusive neuroprotective status following 
TTM.38 It is interesting that despite the aforementioned gaps in knowledge that the ILCOR 
committee was still in favor or recommending TTM initiation for at least 24 hours at to a point of 
at least 32-36C.38 What this shows then is that there is clearly room for pursuing future research 
in therapeutic hypothermia. Recent work seems to be focused on retrospective analysis of 
previous TTM trials, with time spent reworking and reanalyzing the data in hopes of finding 
some new breakthrough.39,40 A recent retrospective analysis published in 2020 for 92 patients 
over the period of 2000 to 2018 found that for ventricular fibrillation, survival to the one year 
mark was significantly improved for those that received TTM vs. those who did not.40 Though 
this study demonstrated some benefit in survival, Koren et. al., went on to say that improvements 
in PCI catheterization have significantly reduced the population size that may have found TTM 
beneficial.40 They go on to say that while the patient population size is increasingly small, there 
may be some bene   TTM     .40 While you 
         -size-fits all situation, the fact that a 
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Why then should be continue to pursue a field with shrinking implementation and questionable 
efficacy in the first place? The future of TTM then it seems hangs on the question of whether the 
time, money, legislative, and administrative red tape is worth fighting through if only to prove 
the treatment effective or not. Research up to this point has led to a crossroads, and eventually, at 
some point someone well educated in the field is going to have to decide if the future of TTM is 
really worth pursuing.  
CONCLUSION 
 The usefulness of Therapeutic Temperature Management appears to be ticking down to 
its final hours. The field in general appears to be a victim of its own early success. While flawed, 
early studies done by the HACA group and Bernard et al., offered real promise for advancement 
in what is otherwise the rather stale field of post-resuscitation care.9,10 Instead of pushing 
forward with studies focused on refining the field and attempting to hone in on a singular, 
successful protocol, it appears that researchers took early successes at face value and were over-
zealous in their expansion. The fact that I had to narrow down my research from a pool of 431 
articles is a testament to the growth of the field       
regarded topic until the early 2000s.  
Unfortunately, it seems that there has not been a consistent direction in which the field 
has progressed in. Instead we ended up with multiple flimsy off-shoots of research with studies 
on the timing of cooling, the varying methods of cooling, and the degree in which cooling is 
effective. The shortcomings of the field stem largely from the fact it is nigh impossible to predict 
when, where, and how someone will suffer a cardiac arrest. This leads to a difficulty in selecting 
a standardized patient population. Enrollment of that population becomes an even bigger issue as 
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everyone in a geographical area somehow has to be consented prio   . I     
to consent a patient prior, you end up having to obtain consent from a family who is now 
grieving a serious medical event. Not only that, but it has also proven difficult to settle on a scale 
that grades neurological outco     .       
              . Without a 
standardized definition of benefit how can it be possible to determine when a treatment is 
actually working to optimal capacity? Additionally, there are so many complicating factors on a 
patient level when someone suffers a cardiac arrest. From diet and previous health status, to 
location of arrest, time down, and availability of resources, all of these make it increasingly 
difficult to create a standardized algorithm. Implementation of the cooling protocol by the 
      . A  I            
arrest can attest, things almost never go to plan. I imagine attempting to stick to a strict sequence 
of actions in order to preserve a research study might not always be the top priority when a 
patient is dying in front of you. All of these patient factors coupled with facility politics, funding, 
and regulatory boards make it nearly impossible to get a standardized group of patients enrolled 
to a study where treatment options could be explored and implemented in a way that some new 
revelation of knowledge might rear its head. 
Further, when looking at the current data is there a legitimate cause to fund another large 
random TTM trial? If somehow a study were able to standardize their patient data, were able to 
ensure protocols were consistently followed, and were able to appropriately without bias perform 
another trial how much better off are we realistically going to be? The cost to patients for TTM is 
astronomical, and though it has gotten better as technology has improved, as future providers we 
would be greatly amiss to not consider the financial aspects of such an involved treatment. 
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Though I think continued work in the area might be able to be justified as evidenced by the 
reviews published by Arrich et al., and Kalra et al., it appears therapeutic hypothermia for post-
cardiac arrest patients is rapidly approaching a crossroads where it would take a new, landmark 
RCT trial of hundreds of patients to conclusively push the field forward in a new direction.4,12 It 
seems that the winds of enthusiasm felt in the early 2000s when therapeutic hypothermia was 
first found successful have quelled, and it appears rather unlikely that they will pick back up 
again. Repeated retrospective studies in the field like the one done by Pavlov et al., have 
attempted to approach old studies with new eyes in order to uncover some new fuel for the fire 
but have come up short in any effective conclusions.39 It seems then that the field will quietly 
pass on, surpassed in efficacy and funding by new catheterization methods and better 
pharmacological care. Based on the research discussed in this paper, I would be hard fought to 
consider TTM as part of my future treatment regimens if the situation presented itself. I look 
forward to the coming years and any additional research that might shift the tides within the 
,         TTM   .   
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Appendix 5  
Cost analysis breakdown including the average cost for TTM associated devices, the items 
highlighted by the arrows are denotation of the standard costs and hours associated with 
TTM training that plays into QALY costs.36 
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